Article info

Download PDFPDF

Original article
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Authors

  1. Correspondence to Dr Vibeke Strand; vstrand{at}stanford.edu
View Full Text

Citation

Strand V, de Vlam K, Covarrubias-Cobos JA, et al
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Publication history

  • Received August 23, 2018
  • Revision received October 18, 2018
  • Accepted October 18, 2018
  • First published January 11, 2019.
Online issue publication 
January 11, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.